Drugs / IL-15 expanded CD4 T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05378464 | May 2022 → Aug 2026 | HER2 positive breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-15 expanded CD4 T cells | “Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.” NCT05378464 ↗ |
| Route | Intravenous | “IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8” NCT05378464 ↗ |